期刊文献+

补中助长颗粒治疗学龄前特发性身材矮小20例临床观察 被引量:10

Clinical observation on 20 cases of idiopathic short stature in preschool children treated with Buzhong Zhuzhang Granules
原文传递
导出
摘要 目的观察补中助长颗粒治疗学龄前特发性身材矮小(ISS)的临床疗效。方法将40例学龄前ISS患儿随机分为对照组和治疗组,对照组给予生活方式干预,治疗组在对照组治疗方法的基础上口服补中助长颗粒,2次/d,4个疗程后比较2组患儿身高(H)、身高增长速度(GV)、身高标准差计数(Ht SDS)、体质量指数(BMI)、年龄/骨龄(CA/BA)、预测成人身高(PAH)的差异以及血清胰岛素样生长因子1(IGF-1)、生长激素激发试验所得生长激素峰值(GHP)的变化。结果治疗后2组BMI,CA/BA比较,差异均无统计学意义(P>0.05),治疗组GV、PAH、血清IGF-1、GHP、Ht SDS高于对照组,差异均有统计学意义(P<0.05或P<0.01)。结论补中助长颗粒能够促进ISS患儿生长,刺激ISS患儿血清IGF-1和生长激素(GH)的表达可能是其作用机制之一。 Objective To observe the clinical effect of idiopathic short stature (ISS) in preschool children trea- ted with Buzhong Zhuzhang Granules. Methods 40 cases of preschool children with ISS were randomly divided in- to control group and therapy group. The control group was given lifestyle intervention, while the therapy group was given Buzhong Zhuzhang Granule twice a day based on the therapy of control group. After 4 courses of treatment, da- ta of children's H,GV,HtSDS, BMI, CA/BA,PAH and changes of IGF-1, GHP were observed and compared. Re- sults After treatment, there were no statistical significant differences in comparison of BMI, CA/B of two groups (P〉0.05). The degree of GV, PAH, IGF-1, GHP, HtSDS in the therapy group were higher than that of control group,differences had statistical significance (P〈0.05 or P〈0.01 ). Conclusion Buzhong Zhuzhang Granules can improve ISS,stimulate IGF-1 and GH.
出处 《中医儿科杂志》 2017年第4期57-60,共4页 Journal of Pediatrics of Traditional Chinese Medicine
基金 河南省中医药科学研究专项课题(2015ZY02115) 河南省中医药研究专项课题(2015ZY02073) 河南省科技攻关项目(162102310063)
关键词 特发性身材矮小 学龄前 补中助长颗粒 临床观察 idiopathic short stature preschool Buzhong Zhuzhang Granules clinical observation
  • 相关文献

参考文献4

二级参考文献44

  • 1中华医学会儿科学分会内分泌遗传代谢学组,王慕逖.矮身材儿童诊治指南[J].中华儿科杂志,2008(6):428-430. 被引量:460
  • 2于意,王伟,王莹,黄嶶,董治亚,滕月春,倪继红,肖园,王德芬.生长激素受体基因多态性与特发性矮小遗传易感性的关系[J].上海交通大学学报(医学版),2011,31(7):932-936. 被引量:12
  • 3李辉,朱宗涵,张德英.2005年中国九市七岁以下儿童体格发育调查[J].中华儿科杂志,2007,45(8):609-614. 被引量:217
  • 4Sklar CA, Mertens AC, Mitby P, et al. Risk of disease re- currence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Child- hood Cancer Survivor Study [ J]. J Clin Endocrinol Metab, 2002, 87(7) :3136-3141.
  • 5Clayton PE, Cowell CT. Safety issues in children and ado- lescents during growth hormone therapy-a review [ J ]. Growth Horm IGF Res, 2000, 10(6) :306-317.
  • 6Burgert TS, Vuguin PM, DiMartino-Nardi J, et al. Assess- ing insulin resistance: application of a fasting glucose to in- sulin ratio in growth hormone-treated children [ J]. Horm Res. 2002. 57(1-2) :37-42.
  • 7Quigley CA, Gill AM, Crowe B J, et al. Safety of growth hormone treatment in pediatric patients with idiopathic short stature [J]. J Clin Endocrinol Metab, 2005, 90(9) :5188- 5196.
  • 8BIethen SL, Allen DB, Graves D, et al. Safety of recombi- nant deoxyribonucleic acid-derived growth hormone: the Na-tional Cooperative Growth Study experience [ J ]. J Clin En- docrinol Metab, 1996, 81(5) :1704-1710.
  • 9Cowell CT, Dietsch S. Adverse events during growth hor- mone therapy [J]. J Pediatr Endocrinol Metab, 1995, 8 (4) :243-252.
  • 10Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment [ J]. Lancet, 2000, 355(9204) :610-613.

共引文献611

同被引文献134

引证文献10

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部